No Detail Found!

Assessment of health-related quality of life in patients with heart failure and reduced ejection fraction taking low-dose sacubitril-valsartan

Author(s)
Kaleem Ullah Sheikh Department of Cardiology,Liaquat National Hospital and Medical College, karachi, Pakistan
Abeer Sarfaraz Department of Cardiology,Liaquat National Hospital and Medical College, karachi, Pakistan
Amna Farooq Department of Cardiology,Liaquat National Hospital and Medical College, karachi, Pakistan
Sanjana Devi Department of Cardiology,Liaquat National Hospital and Medical College, karachi, Pakistan
Sana Shoaib Department of Cardiology,Liaquat National Hospital and Medical College, karachi, Pakistan
Abstract
Objective: To examine the impact of administering low-dose sacubitril-valsartan on the quality of health in individ­uals suffering from heart failure and reduced ejection fraction. Methodology: It is a prospective, cohort study comprising n=77 heart failure patients from a Tertiary Care Hospital with low ejection fraction. An FDA-approved KCCQ questionnaire was used for data collection at admission and after a 6-week follow-up. Descriptive statistics were reported in terms of percentage and mean± Std. dev. For mean comparison paired t-test was used. P value <0.05 was considered statistically significant. esults: Out of 77 patients, 28 (36.4%) were women and 49 (63.6%) were men. The study included participants with an average age of 60.05±11.80 years. Among the participants, 68.8% had hypertension and 51.9% had diabetes. 29.9% of the patients included had an EF of 30%, 49.3% had it between 31-39%, and 20.8% had an EF of 40%. Regarding classification by New York Heart Association (NYHA), before initiating Sacubitril/Valsartan, around 84.4% of patients were categorized as class 3, while 15.6% as class 4. Six weeks after therapy 79.2% of patients improved to functional class 2 and 20.8% to class 3. Statistical analysis revealed a significant difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores of heart failure patients when comparing scores prior to and after receiving treatment of sacubitril/valsartan, 24/26mg BID. Conclusion: The study showed that patients with heart failure having a low ejection fraction experienced an im­provement in quality of life as judged by KCCQ scores even while using sacubitril-valsartan at a low dose
Publication Details
Page(s) 166-170
Published Journal: Journal of Postgraduate Medical Institute, Volume: 37, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
Heart failure, Health-related quality of life, Reduced Ejection Fraction
0

Citations

0

Downloads

44

Views